Kristen Cox Appointed to Texas Medical Board District Two Review Committee

Publisher's Picks
407

Listen to article (english)

Translate to Spanish or other 102 languages!

Governor Greg Abbott has appointed Kristen Cox to the Texas Medical Board District Two Review Committee for a term set to expire on January 15, 2024. Image Source; LinkedIN for illustration purposes
Governor Greg Abbott has appointed Kristen Cox to the Texas Medical Board District Two Review Committee for a term set to expire on January 15, 2024. Image Source; LinkedIN for illustration purposes

Mega Doctor News

- Advertisement -

AUSTIN, Texas — Governor Greg Abbott has appointed Kristen Cox to the Texas Medical Board District Two Review Committee for a term set to expire on January 15, 2024.

Kristen Cox of College Station is president and chief executive officer of Checkpoint Services, Inc., and 12th Man Technology. She served for 12 years as a gubernatorial appointee on the Texas Council for Developmental Disabilities. She was a founding board member of El Paso Children’s Hospital and served on the El Paso Children’s Hospital Foundation board. Previously, she served on the boards of Make-A-Wish of El Paso, National Center for Missing & Exploited Children, Alzheimer’s Association, and Rotary Clubs of College Station and El Paso. Cox received a Bachelor of Science in Engineering from Texas A&M University and a Master of Business Administration from The University of Texas at Dallas.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Boys & Girls Club of Pharr – San Juan Hosts 2023 Teen Mental Health Camp
Next article
 ‘CHALK THE WALK’ Event Raises Suicide Awareness

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -